Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Kevin T Conroy. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Kevin T Conroy har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:ALGN / Align Technology, Inc. | Director | 1 808 |
US:EXAS / Exact Sciences Corporation | President and CEO, Director | 0 |
US:ADPT / Adaptive Biotechnologies Corporation | Director | 22 968 |
US:EPZM / Epizyme Inc | Director | 0 |
US:US83444K1135 / SomaLogic Inc | Director | 0 |
Director | 0 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Kevin T Conroy. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Internkjøp ADPT / Adaptive Biotechnologies Corporation - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i ADPT / Adaptive Biotechnologies Corporation. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel ADPT / Adaptive Biotechnologies Corporation - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i ADPT / Adaptive Biotechnologies Corporation. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Kevin T Conroy som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-05-22 |
|
4 | ALGN |
ALIGN TECHNOLOGY INC
Common Stock |
M - Exercise | 1 148 | 1 808 | 173,94 | ||||
2025-04-29 |
|
5/A | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −22 063 | 0 | −100,00 | ||||
2025-04-29 |
|
5/A | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −43 126 | 22 063 | −66,16 | ||||
2025-04-29 |
|
5/A | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | 43 126 | 893 818 | 5,07 | ||||
2025-04-29 |
|
5/A | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −28 660 | 850 692 | −3,26 | ||||
2025-04-29 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −163 000 | 602 120 | −21,30 | ||||
2025-04-29 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −74 599 | 779 944 | −8,73 | ||||
2025-03-10 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −48 929 | 1 154 340 | −4,07 | 47,06 | −2 302 599 | 54 323 240 | |
2025-03-10 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 66 723 | 1 203 269 | 5,87 | 22,38 | 1 493 261 | 26 929 160 | |
2025-03-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −10 419 | 1 136 546 | −0,91 | 47,82 | −498 237 | 54 349 630 | |
2025-03-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 22 167 | 1 146 965 | 1,97 | ||||
2025-03-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −8 528 | 1 124 798 | −0,75 | 47,82 | −407 809 | 53 787 840 | |
2025-03-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 18 143 | 1 133 326 | 1,63 | ||||
2025-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −6 195 | 1 115 183 | −0,55 | 51,28 | −317 680 | 57 186 584 | |
2025-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 13 180 | 1 121 378 | 1,19 | ||||
2025-02-21 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −21 140 | 1 108 198 | −1,87 | 50,48 | −1 067 147 | 55 941 835 | |
2025-02-21 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 48 044 | 1 129 338 | 4,44 | ||||
2025-02-21 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −3 271 | 1 081 294 | −0,30 | 49,63 | −162 340 | 53 664 621 | |
2025-02-21 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 10 374 | 1 084 565 | 0,97 | ||||
2024-11-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
P - Purchase | 19 500 | 1 074 191 | 1,85 | 51,35 | 1 001 325 | 55 159 708 | |
2024-05-24 |
|
4 | ALGN |
ALIGN TECHNOLOGY INC
Common Stock |
M - Exercise | 660 | 660 | |||||
2024-05-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −1 155 | 1 156 191 | −0,10 | 60,15 | −69 473 | 69 544 889 |
2024-05-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 708 | 1 157 346 | 0,06 | 30,02 | 21 254 | 34 743 527 | |
2024-05-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 2 489 | 1 156 638 | 0,22 | ||||
2024-03-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −8 271 | 1 299 496 | −0,63 | 59,32 | −490 636 | 77 086 103 |
2024-03-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 18 143 | 1 307 767 | 1,41 | ||||
2024-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −6 263 | 1 289 624 | −0,48 | 56,89 | −356 302 | 73 366 709 |
2024-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 13 181 | 1 295 887 | 1,03 | ||||
2024-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −61 560 | 1 282 706 | −4,58 | 57,53 | −3 541 547 | 73 794 076 | |
2024-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 102 837 | 1 344 266 | 8,28 | 13,96 | 1 435 605 | 18 765 953 | |
2024-02-23 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −11 565 | 1 241 429 | −0,92 | 59,78 | −691 356 | 74 212 626 |
2024-02-23 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 23 238 | 1 252 994 | 1,89 | ||||
2024-02-22 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −4 975 | 1 229 756 | −0,40 | 61,50 | −305 962 | 75 629 994 |
2024-02-22 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 10 374 | 1 234 731 | 0,85 | ||||
2024-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −14 791 | 1 224 357 | −1,19 | 61,43 | −908 611 | 75 212 251 |
2024-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 31 133 | 1 239 148 | 2,58 | ||||
2024-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 709 | 1 208 015 | 0,06 | 30,02 | 21 284 | 36 264 610 | |
2023-03-08 |
|
4 | ADPT |
Adaptive Biotechnologies Corp
Common Stock |
A - Award | 14 775 | 22 968 | 180,34 | ||||
2023-03-01 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −10 416 | 1 207 306 | −0,86 | 61,12 | −636 626 | 73 790 543 |
2023-03-01 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 9 312 | 1 217 722 | 0,77 | ||||
2023-03-01 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 13 180 | 1 208 410 | 1,10 | ||||
2023-02-23 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −4 764 | 1 195 230 | −0,40 | 62,72 | −298 798 | 74 964 826 |
2023-02-23 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 10 374 | 1 199 994 | 0,87 | ||||
2023-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −14 617 | 1 189 620 | −1,21 | 65,59 | −958 729 | 78 027 176 | |
2023-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 31 132 | 1 204 237 | 2,65 | ||||
2023-02-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −4 527 | 1 173 105 | −0,38 | 64,55 | −292 218 | 75 723 928 |
2023-02-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 9 705 | 1 177 632 | 0,83 | ||||
2022-08-16 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
D - Sale to Issuer | −8 994 | 0 | −100,00 | ||||
2022-08-16 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
D - Sale to Issuer | −53 324 | 8 994 | −85,57 | ||||
2022-07-06 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −7 | 1 167 927 | 0,00 | 40,75 | −285 | 47 593 025 |
2022-07-06 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 328 | 1 167 934 | 0,03 | 47,41 | 15 550 | 55 371 751 | |
2022-07-05 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 10 204 | 62 318 | 19,58 | 1,47 | 15 000 | 91 607 | |
2022-05-19 |
|
4 | EPZM |
Epizyme, Inc.
Stock Option (Right to Buy) |
A - Award | 41 006 | 41 006 | |||||
2022-05-19 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 8 994 | 52 114 | 20,86 | ||||
2022-04-01 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 13 043 | 43 120 | 43,37 | 1,15 | 14 999 | 49 588 | |
2022-03-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −2 253 | 66 047 | −3,30 | ||||
2022-03-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −4 612 | 235 388 | −1,92 | ||||
2022-03-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −229 757 | 0 | −100,00 | ||||
2022-03-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 2 253 | 1 167 606 | 0,19 | 44,37 | 99 966 | 51 806 678 | |
2022-03-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 4 612 | 1 165 353 | 0,40 | 21,68 | 99 988 | 25 264 853 | |
2022-03-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 229 757 | 1 160 741 | 24,68 | 5,70 | 1 309 615 | 6 616 224 | |
2022-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −14 299 | 930 984 | −1,51 | 76,69 | −1 096 590 | 71 397 163 |
2022-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −9 312 | 9 312 | −50,00 | ||||
2022-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 575 | 0 | −100,00 | ||||
2022-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 9 312 | 945 283 | 0,99 | ||||
2022-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 575 | 935 971 | 2,25 | ||||
2022-03-01 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 52 722 | 52 722 | |||||
2022-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −27 126 | 915 396 | −2,88 | 70,10 | −1 901 533 | 64 169 260 |
2022-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Performance Stock Units |
M - Exercise | −58 643 | 0 | −100,00 | ||||
2022-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 58 643 | 942 522 | 6,63 | ||||
2022-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −5 188 | 883 879 | −0,58 | 69,05 | −358 231 | 61 031 845 |
2022-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −10 373 | 31 122 | −25,00 | ||||
2022-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 10 373 | 889 067 | 1,18 | ||||
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −14 409 | 878 694 | −1,61 | 79,55 | −1 146 236 | 69 900 108 |
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −31 133 | 62 265 | −33,33 | ||||
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −96 758 | 0 | −100,00 | ||||
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −94 425 | 0 | −100,00 | ||||
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 31 133 | 893 103 | 3,61 | 78,33 | 2 438 648 | 69 956 758 | |
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 96 758 | 861 970 | 12,64 | 10,82 | 1 046 922 | 9 326 515 | |
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 94 425 | 765 212 | 14,08 | 9,07 | 856 435 | 6 940 473 | |
2022-01-28 |
|
4 | ADPT |
Adaptive Biotechnologies Corp
Stock Option (Right to Buy) |
A - Award | 16 722 | 16 722 | |||||
2022-01-28 |
|
4 | ADPT |
Adaptive Biotechnologies Corp
Common Stock |
A - Award | 6 689 | 8 193 | 444,75 | ||||
2022-01-19 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 6 407 | 670 787 | 0,96 | ||||
2022-01-04 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 6 000 | 30 077 | 24,92 | 2,50 | 15 000 | 75 192 | |
2021-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −16 922 | 664 380 | −2,48 | 93,88 | −1 588 637 | 62 371 994 |
2021-10-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −17 078 | 681 302 | −2,45 | 93,64 | −1 599 184 | 63 797 119 |
2021-10-01 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 2 930 | 24 077 | 13,86 | 5,12 | 15 002 | 123 274 | |
2021-09-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −18 978 | 698 380 | −2,65 | 104,42 | −1 981 683 | 72 924 840 |
2021-09-03 |
|
4 | SLGCW |
SomaLogic, Inc.
Class B Common Stock |
M - Exercise | −25 000 | 0 | −100,00 | ||||
2021-09-03 |
|
4 | SLGCW |
SomaLogic, Inc.
Warrants to purchase Class A Common Stock (right to buy) |
A - Award | 166 666 | 166 666 | |||||
2021-09-03 |
|
4 | SLGCW |
SomaLogic, Inc.
Class A Common Stock |
J - Other | 25 000 | 25 000 | |||||
2021-08-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −19 970 | 717 358 | −2,71 | 107,50 | −2 146 775 | 77 115 985 |
2021-07-06 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −7 784 | 737 328 | −1,04 | 123,43 | −960 779 | 91 008 395 |
2021-07-01 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 1 805 | 21 147 | 9,33 | 8,31 | 15 000 | 175 732 | |
2021-06-15 |
|
4 | EPZM |
Epizyme, Inc.
Stock Option (Right to Buy) |
A - Award | 40 559 | 40 559 | |||||
2021-06-15 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 8 060 | 19 342 | 71,44 | ||||
2021-06-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −12 384 | 745 112 | −1,63 | 111,00 | −1 374 624 | 82 707 432 |
2021-05-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −19 240 | 757 496 | −2,48 | 131,09 | −2 522 172 | 99 300 151 |
2021-05-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 328 | 776 736 | 0,04 | 64,74 | 21 235 | 50 285 889 | |
2021-04-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −22 755 | 776 408 | −2,85 | 132,30 | −3 010 486 | 102 718 778 |
2021-04-01 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 1 723 | 11 282 | 18,02 | 8,71 | 15 007 | 98 266 | |
2021-03-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 796 | 799 163 | −1,21 | 138,42 | −1 355 962 | 110 620 142 |
2021-03-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 575 | 20 575 | −50,00 | ||||
2021-03-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 575 | 808 959 | 2,61 | ||||
2021-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −26 958 | 788 384 | −3,31 | 136,79 | −3 687 585 | 107 843 047 |
2021-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −4 335 | 815 342 | −0,53 | 137,44 | −595 802 | 112 060 604 |
2021-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −9 312 | 18 624 | −33,33 | ||||
2021-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 9 312 | 819 677 | 1,15 | ||||
2021-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −16 420 | 810 365 | −1,99 | 136,30 | −2 238 046 | 110 452 750 |
2021-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −34 325 | 0 | −100,00 | ||||
2021-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 34 325 | 826 785 | 4,33 | ||||
2021-02-23 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 41 495 | 41 495 | |||||
2021-02-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −15 825 | 792 460 | −1,96 | 142,66 | −2 257 594 | 113 052 344 |
2021-02-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −31 132 | 93 398 | −25,00 | ||||
2021-02-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 31 132 | 808 285 | 4,01 | ||||
2021-02-17 |
|
4 | ADPT |
Adaptive Biotechnologies Corp
Stock Option (Right to Buy) |
A - Award | 3 759 | 3 759 | |||||
2021-02-17 |
|
4 | ADPT |
Adaptive Biotechnologies Corp
Common Stock |
A - Award | 1 504 | 1 504 | |||||
2021-02-09 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −17 543 | 229 757 | −7,09 | ||||
2021-02-09 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 17 543 | 777 153 | 2,31 | 5,70 | 99 995 | 4 429 772 | |
2021-02-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −30 344 | 759 610 | −3,84 | 138,07 | −4 189 596 | 104 879 353 |
2021-02-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −35 750 | 789 954 | −4,33 | ||||
2021-01-07 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −31 814 | 825 704 | −3,71 | 128,74 | −4 095 734 | 106 301 133 |
2021-01-05 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 1 024 | 9 559 | 12,00 | 10,86 | 11 121 | 103 811 | |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −100 | 857 518 | −0,01 | 126,59 | −12 659 | 108 553 204 |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −100 | 857 618 | −0,01 | 126,49 | −12 649 | 108 480 101 |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −7 043 | 857 718 | −0,81 | 125,92 | −886 855 | 108 003 851 |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −10 840 | 864 761 | −1,24 | 124,88 | −1 353 699 | 107 991 354 |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −7 776 | 875 601 | −0,88 | 124,03 | −964 457 | 108 600 792 |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −2 918 | 883 377 | −0,33 | 122,91 | −358 651 | 108 575 867 |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −1 800 | 886 295 | −0,20 | 122,05 | −219 690 | 108 172 305 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −400 | 888 095 | −0,05 | 124,71 | −49 884 | 110 754 327 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −600 | 888 495 | −0,07 | 123,45 | −74 070 | 109 684 708 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 577 | 889 095 | −1,07 | 122,33 | −1 171 554 | 108 762 991 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −10 229 | 898 672 | −1,13 | 121,52 | −1 243 028 | 109 206 621 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −6 512 | 908 901 | −0,71 | 120,45 | −784 370 | 109 477 125 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −1 108 | 915 413 | −0,12 | 119,18 | −132 051 | 109 098 921 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −4 393 | 916 521 | −0,48 | 118,32 | −519 780 | 108 442 765 |
2020-10-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −1 136 | 920 914 | −0,12 | 105,20 | −119 507 | 96 880 153 |
2020-10-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −5 200 | 922 050 | −0,56 | 104,70 | −544 440 | 96 538 635 |
2020-10-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 391 | 927 250 | −1,00 | 103,57 | −972 626 | 96 035 282 |
2020-10-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −11 698 | 936 641 | −1,23 | 102,86 | −1 203 256 | 96 342 893 |
2020-10-01 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 933 | 8 535 | 12,27 | 11,93 | 11 131 | 101 823 | |
2020-09-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −19 927 | 948 339 | −2,06 | 75,03 | −1 495 123 | 71 153 875 |
2020-08-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −198 | 968 266 | −0,02 | 95,00 | −18 810 | 91 985 270 |
2020-08-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −25 000 | 968 464 | −2,52 | 93,79 | −2 344 750 | 90 832 239 |
2020-08-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 501 | 993 464 | 0,05 | 42,44 | 21 262 | 42 162 612 | |
2020-07-06 |
|
4 | ARYA |
ARYA SCIENCES ACQUISITION CORP.
Class B Ordinary Shares |
D - Sale to Issuer | −30 000 | 0 | −100,00 | ||||
2020-07-01 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 693 | 7 602 | 10,03 | 16,06 | 11 130 | 122 088 | |
2020-06-02 |
|
4 | EPZM |
Epizyme, Inc.
Stock Option (Right to Buy) |
A - Award | 14 013 | 14 013 | |||||
2020-04-02 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 717 | 6 909 | 11,58 | 15,51 | 11 121 | 107 159 | |
2020-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 750 | 992 963 | −0,97 | 80,17 | −781 658 | 79 605 844 |
2020-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 575 | 41 150 | −33,33 | ||||
2020-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 575 | 1 002 713 | 2,09 | ||||
2020-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −13 875 | 982 138 | −1,39 | 80,27 | −1 113 746 | 78 836 217 |
2020-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −9 312 | 27 936 | −25,00 | ||||
2020-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 025 | 0 | −100,00 | ||||
2020-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 9 312 | 996 013 | 0,94 | ||||
2020-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 025 | 986 701 | 2,07 | ||||
2020-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −18 115 | 966 676 | −1,84 | 85,11 | −1 541 768 | 82 273 794 |
2020-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −34 325 | 34 325 | −50,00 | ||||
2020-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 34 325 | 984 791 | 3,61 | ||||
2020-02-18 |
|
4 | ADPT |
Adaptive Biotechnologies Corp
Stock Option (Right to Buy) |
A - Award | 8 888 | 8 888 | |||||
2020-02-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 124 530 | 124 530 | |||||
2020-02-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 100 916 | 100 916 | |||||
2020-02-14 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | 21 729 | 21 729 | |||||
2020-02-14 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | 21 730 | 21 730 | |||||
2020-02-14 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | 21 730 | 21 730 | |||||
2020-02-14 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −65 189 | 0 | −100,00 | ||||
2020-01-03 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 452 | 6 192 | 7,87 | 24,60 | 11 119 | 152 323 | |
2019-12-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −4 277 | 66 723 | −6,02 | ||||
2019-12-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −7 163 | 102 837 | −6,51 | ||||
2019-12-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 4 277 | 950 466 | 0,45 | 23,38 | 99 996 | 22 221 895 | |
2019-12-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 7 163 | 946 189 | 0,76 | 13,96 | 99 995 | 13 208 798 | |
2019-12-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 500 | 939 026 | 0,05 | 42,44 | 21 220 | 39 852 263 | |
2019-10-02 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 1 078 | 5 740 | 23,12 | 10,32 | 11 125 | 59 237 | |
2019-07-02 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 887 | 4 662 | 23,50 | 12,55 | 11 132 | 58 508 | |
2019-06-07 |
|
4 | EPZM |
Epizyme, Inc.
Stock Option (Right to Buy) |
A - Award | 17 633 | 17 633 | |||||
2019-06-07 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 897 | 3 775 | 31,17 | 12,39 | 11 114 | 46 772 | |
2019-03-12 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −11 227 | 938 526 | −1,18 | 87,21 | −979 129 | 81 850 730 |
2019-03-12 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −24 400 | 0 | −100,00 | ||||
2019-03-12 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 24 400 | 949 753 | 2,64 | ||||
2019-03-01 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −10 014 | 925 353 | −1,07 | 93,20 | −933 345 | 86 246 601 |
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 575 | 61 725 | −25,00 | ||||
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 575 | 935 367 | 2,25 | ||||
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 169 | 914 792 | −0,99 | 95,07 | −871 734 | 86 972 935 |
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 37 248 | 37 248 | |||||
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 34 110 | 34 110 | |||||
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 025 | 20 025 | −50,00 | ||||
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 025 | 923 961 | 2,22 | ||||
2019-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −16 400 | 903 936 | −1,78 | 90,55 | −1 485 036 | 81 852 309 |
2019-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −34 325 | 68 650 | −33,33 | ||||
2019-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 34 325 | 920 336 | 3,87 | ||||
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −23 236 | 886 011 | −2,56 | 82,49 | −1 916 668 | 73 084 389 |
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −181 250 | 909 247 | −16,62 | 81,90 | −14 844 194 | 74 466 420 |
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −36 453 | 1 090 497 | −3,23 | 80,78 | −2 944 783 | 88 093 619 |
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −28 605 | 1 126 950 | −2,48 | 79,89 | −2 285 339 | 90 035 416 |
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −34 853 | 1 155 555 | −2,93 | 78,80 | −2 746 416 | 91 057 734 |
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Performance Share Units |
M - Exercise | −304 397 | 0 | −100,00 | ||||
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 304 397 | 1 190 408 | 34,36 | ||||
2019-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Performance Share Units |
A - Award | 304 397 | 304 397 | |||||
2018-11-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −163 514 | 0 | −100,00 | ||||
2018-11-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −163 514 | 886 011 | −15,58 | 69,00 | −11 282 466 | 61 134 759 |
2018-11-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 163 514 | 1 049 525 | 18,46 | 0,83 | 135 717 | 871 106 | |
2018-11-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 3 572 | 886 011 | 0,40 | 5,95 | 21 253 | 5 271 765 | |
2018-07-02 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 2 878 | 2 878 | 13,55 | 38 997 | 38 997 | ||
2018-05-31 |
|
4 | EPZM |
Epizyme, Inc.
Stock Option (Right to Buy) |
A - Award | 12 500 | 12 500 | |||||
2018-03-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −11 459 | 882 439 | −1,28 | 52,19 | −598 091 | 46 058 021 |
2018-03-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −24 400 | 24 400 | −50,00 | ||||
2018-03-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 24 400 | 893 898 | 2,81 | ||||
2018-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 82 300 | 82 300 | |||||
2018-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 68 300 | 68 300 | |||||
2018-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 085 | 869 498 | −1,03 | 44,10 | −400 630 | 38 343 123 |
2018-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 025 | 40 050 | −33,33 | ||||
2018-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 025 | 878 583 | 2,33 | ||||
2018-02-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −25 319 | 858 558 | −2,86 | 42,34 | −1 071 956 | 36 349 629 |
2018-02-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 500 | 0 | −100,00 | ||||
2018-02-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 500 | 883 877 | 2,26 | ||||
2018-02-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −34 325 | 102 975 | −25,00 | ||||
2018-02-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 34 325 | 864 377 | 4,14 | ||||
2018-02-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −101 488 | 163 514 | −38,30 | ||||
2018-02-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −9 458 | 830 052 | −1,13 | 46,29 | −437 839 | 38 425 597 | |
2018-02-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −50 504 | 839 510 | −5,67 | 46,54 | −2 350 456 | 39 070 795 | |
2018-02-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −41 526 | 890 014 | −4,46 | 44,60 | −1 851 977 | 39 692 844 | |
2018-02-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | X | 101 488 | 931 540 | 12,23 | 0,83 | 84 235 | 773 178 |
2018-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −110 439 | 265 002 | −29,42 | ||||
2018-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −30 036 | 830 052 | −3,49 | 51,66 | −1 551 660 | 42 880 486 | |
2018-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −41 588 | 860 088 | −4,61 | 50,72 | −2 109 427 | 43 625 384 | |
2018-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −26 738 | 901 676 | −2,88 | 49,54 | −1 324 707 | 44 672 636 | |
2018-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −12 077 | 928 414 | −1,28 | 48,87 | −590 167 | 45 368 807 | |
2018-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | X | 110 439 | 940 491 | 13,31 | 0,83 | 91 664 | 780 608 |
2018-01-17 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −125 402 | 375 441 | −25,04 | ||||
2018-01-17 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −25 912 | 830 052 | −3,03 | 53,24 | −1 379 659 | 44 195 289 | |
2018-01-17 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −99 490 | 855 964 | −10,41 | 52,68 | −5 240 934 | 45 090 472 | |
2018-01-17 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | X | 125 402 | 955 454 | 15,11 | 0,83 | 104 084 | 793 027 |
2017-12-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −123 512 | 500 843 | −19,78 | ||||
2017-12-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −27 065 | 830 052 | −3,16 | 53,36 | −1 444 053 | 44 287 424 |
2017-12-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −96 447 | 857 117 | −10,11 | 52,37 | −5 050 736 | 44 885 503 |
2017-12-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 123 512 | 953 564 | 14,88 | 0,83 | 102 515 | 791 458 | |
2017-12-08 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −121 849 | 624 355 | −16,33 | ||||
2017-12-08 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −28 370 | 830 052 | −3,30 | 53,80 | −1 526 448 | 44 660 948 |
2017-12-08 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −93 479 | 858 422 | −9,82 | 53,35 | −4 986 731 | 45 793 380 |
2017-12-08 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 121 849 | 951 901 | 14,68 | 0,83 | 101 135 | 790 078 | |
2017-11-22 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −134 057 | 746 204 | −15,23 | ||||
2017-11-22 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −134 057 | 830 052 | −13,90 | 59,50 | −7 976 660 | 49 389 754 |
2017-11-22 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 134 057 | 964 109 | 16,15 | 0,83 | 111 267 | 800 210 | |
2017-11-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −137 815 | 880 261 | −13,54 | ||||
2017-11-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −5 424 | 830 052 | −0,65 | 60,05 | −325 690 | 49 841 302 |
2017-11-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −80 405 | 835 486 | −8,78 | 59,43 | −4 778 550 | 49 653 768 |
2017-11-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −51 976 | 915 891 | −5,37 | 58,59 | −3 045 430 | 53 664 801 |
2017-11-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 137 815 | 967 867 | 16,60 | 0,83 | 114 386 | 803 330 | |
2017-08-17 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −9 242 | 96 758 | −8,72 | ||||
2017-08-17 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 9 242 | 830 052 | 1,13 | 10,82 | 99 998 | 8 981 163 | |
2017-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 137 300 | 137 300 | |||||
2017-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 240 000 | 240 000 | |||||
2017-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 3 571 | 820 810 | 0,44 | 5,95 | 21 247 | 4 883 820 | |
2017-03-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −12 059 | 817 239 | −1,45 | 21,16 | −255 168 | 17 292 777 |
2017-03-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −24 400 | 48 800 | −33,33 | ||||
2017-03-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 24 400 | 829 298 | 3,03 | ||||
2017-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −19 557 | 804 898 | −2,37 | 21,48 | −420 084 | 17 289 209 |
2017-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 025 | 60 075 | −25,00 | ||||
2017-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 025 | 824 455 | 2,49 | ||||
2017-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 500 | 19 500 | −50,00 | ||||
2017-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 500 | 804 430 | 2,48 | ||||
2017-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −7 577 | 784 930 | −0,96 | 21,57 | −163 436 | 16 930 940 |
2017-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 375 | 0 | −100,00 | ||||
2017-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 375 | 792 507 | 2,51 | ||||
2017-02-07 |
|
4 | EPZM |
Epizyme, Inc.
Stock Option (Right to Buy) |
A - Award | 25 000 | 25 000 | |||||
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −33 075 | 94 425 | −25,94 | ||||
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 33 075 | 773 132 | 4,47 | 9,07 | 299 990 | 7 012 307 | |
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −275 000 | 740 057 | −27,09 | 17,36 | −4 774 000 | 12 847 390 | |
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −275 000 | 1 015 057 | −21,32 | 17,52 | −4 818 000 | 17 783 799 | |
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −600 000 | 1 018 076 | −37,08 | ||||
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −50 000 | 1 290 057 | −3,73 | 17,68 | −884 000 | 22 808 208 | |
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 600 000 | 1 340 057 | 81,07 | 0,83 | 498 000 | 1 112 247 | |
2016-07-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −25 000 | 0 | −100,00 | ||||
2016-07-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 25 000 | 740 057 | 3,50 | ||||
2016-07-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 2 750 | 715 057 | 0,39 | 5,95 | 16 362 | 4 254 589 | |
2016-03-11 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −24 400 | 73 200 | −25,00 | ||||
2016-03-11 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 24 400 | 712 307 | 3,55 | ||||
2016-03-11 |
|
4/A | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 80 100 | 80 100 | |||||
2016-03-11 |
|
4/A | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 247 300 | 247 300 | |||||
2016-03-11 |
|
4/A | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −6 895 | 637 907 | −1,07 | 5,81 | −40 060 | 3 706 240 |
2016-03-01 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
P - Purchase | X | 50 000 | 687 907 | 7,84 | 5,00 | 250 000 | 3 439 535 |
2016-02-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −6 895 | 637 907 | −1,07 | 5,81 | −40 060 | 3 706 240 |
2016-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 500 | 39 000 | −33,33 | ||||
2016-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 500 | 644 802 | 3,12 | ||||
2016-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −6 866 | 625 302 | −1,09 | 6,39 | −43 874 | 3 995 680 |
2016-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 375 | 19 375 | −50,00 | ||||
2016-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 375 | 632 168 | 3,16 | ||||
2016-01-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −265 924 | 1 618 076 | −14,11 | ||||
2016-01-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 265 924 | 612 973 | 76,62 | 0,83 | 220 717 | 508 768 | |
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −10 750 | 346 869 | −3,01 | 8,72 | −93 740 | 3 024 698 |
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 466 | 0 | −100,00 | ||||
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 466 | 357 619 | 6,07 | ||||
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −787 | 337 153 | −0,23 | ||||
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −340 | 337 940 | −0,10 | ||||
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −1 000 | 338 280 | −0,29 | ||||
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −395 | 339 280 | −0,12 | ||||
2015-12-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −81 000 | 1 884 000 | −4,12 | ||||
2015-12-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 81 000 | 338 335 | 31,48 | 0,83 | 67 230 | 280 818 | |
2015-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −11 386 | 257 335 | −4,24 | 24,04 | −273 719 | 6 186 333 |
2015-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −25 000 | 25 000 | −50,00 | ||||
2015-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 25 000 | 268 721 | 10,26 | ||||
2015-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 1 195 | 244 061 | 0,49 | 17,78 | 21 247 | 4 339 405 | |
2015-03-11 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 97 600 | 97 600 | |||||
2015-03-11 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 71 000 | 71 000 | |||||
2015-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −8 425 | 243 866 | −3,34 | 23,44 | −197 482 | 5 716 219 |
2015-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 500 | 58 500 | −25,00 | ||||
2015-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 500 | 252 291 | 8,38 | ||||
2015-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 798 | 232 791 | −4,04 | 22,90 | −224 374 | 5 330 914 |
2015-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 375 | 38 750 | −33,33 | ||||
2015-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 375 | 242 589 | 8,68 | ||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 484 | 223 214 | −4,08 | 26,72 | −253 412 | 5 964 278 |
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 467 | 20 466 | −50,00 | ||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 467 | 232 698 | 9,64 | ||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −1 025 | 212 231 | −0,48 | ||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −583 | 213 256 | −0,27 | ||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | 65 189 | 65 189 | |||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −65 189 | 213 839 | −23,36 | ||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −1 535 | 279 028 | −0,55 | ||||
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −135 000 | 1 965 000 | −6,43 | ||||
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | X | −133 334 | 2 100 000 | −5,97 | |||
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 135 000 | 280 563 | 92,74 | 0,83 | 112 050 | 232 867 | |
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −133 334 | 145 563 | −47,81 | 23,93 | −3 190 989 | 3 483 657 |
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | X | 133 334 | 278 897 | 91,60 | 0,83 | 110 667 | 231 485 |
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | X | −133 333 | 2 233 334 | −5,63 | |||
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −133 333 | 145 563 | −47,81 | 23,68 | −3 157 632 | 3 447 267 |
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | X | 133 333 | 278 896 | 91,60 | 0,83 | 110 666 | 231 484 |
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | X | −133 333 | 2 366 667 | −5,33 | |||
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −133 333 | 145 563 | −47,81 | 22,84 | −3 045 566 | 3 324 921 |
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | X | 133 333 | 278 896 | 91,60 | 0,83 | 110 666 | 231 484 |
2014-07-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −25 000 | 50 000 | −33,33 | ||||
2014-07-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −11 336 | 145 563 | −7,23 | 15,99 | −181 263 | 2 327 552 |
2014-07-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 25 000 | 156 899 | 18,95 | ||||
2014-07-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 2 721 | 131 899 | 2,11 | 7,81 | 21 251 | 1 030 131 | |
2014-06-20 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −4 092 | 118 511 | −3,34 | ||||
2014-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 78 000 | 78 000 | |||||
2014-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 110 000 | 110 000 | |||||
2014-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −8 708 | 134 374 | −6,09 | 14,07 | −122 522 | 1 890 642 |
2014-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 375 | 143 082 | 15,66 | ||||
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 271 | 123 707 | −6,97 | 11,96 | −110 881 | 1 479 536 |
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −17 108 | 112 511 | −13,20 | 11,96 | −204 612 | 1 345 632 |
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 467 | 40 933 | −33,33 | ||||
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 61 400 | 61 400 | |||||
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −37 767 | 0 | −100,00 | ||||
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 467 | 132 978 | 18,19 | ||||
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 37 767 | 129 619 | 41,12 | ||||
2013-07-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 75 000 | 75 000 | |||||
2013-07-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 5 082 | 91 852 | 5,86 | 7,81 | 39 690 | 717 364 | |
2013-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 77 500 | 77 500 | |||||
2013-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 106 000 | 106 000 | |||||
2013-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −37 767 | 37 768 | −50,00 | ||||
2013-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −16 410 | 86 770 | −15,90 | 10,59 | −173 782 | 918 894 | |
2013-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 37 767 | 103 180 | 57,74 | ||||
2013-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −1 500 | 65 413 | −2,24 | ||||
2012-11-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
P - Purchase | 2 000 | 66 913 | 3,08 | 9,13 | 18 260 | 610 916 | |
2012-11-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 3 277 | 64 913 | 5,32 | 5,48 | 17 958 | 355 723 | |
2012-11-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 2 528 | 61 636 | 4,28 | 5,48 | 13 853 | 337 765 | |
2012-11-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −995 | 59 108 | −1,66 | ||||
2012-11-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −2 115 | 60 103 | −3,40 | ||||
2012-02-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 127 500 | 127 500 | |||||
2012-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −37 767 | 75 533 | −33,33 | ||||
2012-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 113 300 | 113 300 | |||||
2012-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −16 410 | 62 218 | −20,87 | 8,12 | −133 249 | 505 210 | |
2012-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 37 767 | 78 628 | 92,43 | ||||
2012-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −2 890 | 40 861 | −6,61 | ||||
2012-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −2 919 | 43 751 | −6,25 |